Neuralstem Receives FDA Approval To Commence Spinal Cord Injury Trial
Posted on January 14, 2013 at 11:15 AM EST
Neuralstem, Inc. (NYSE MKT: CUR) announced that it received approval from the United States Food and Drug Administration (FDA) to commence a Phase I safety trial of its lead cell therapy candidate, NSI-566, in chronic spinal cord injury patients. This open-label, multi-site study, will enroll up to eight patients with thoracic spinal cord injuries (T2-T12),